Abstract
In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir Pressair); and siponimod (Mayzent).
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Azetidines / therapeutic use
-
Benzyl Compounds / therapeutic use
-
Carbamates / therapeutic use
-
Clobetasol / analogs & derivatives
-
Clobetasol / therapeutic use
-
Drug Approval*
-
Drug Combinations
-
Formoterol Fumarate / therapeutic use
-
Heterocyclic Compounds, 3-Ring / therapeutic use
-
Humans
-
Lamivudine / therapeutic use
-
Nicotinic Acids / therapeutic use
-
Oxazines
-
Phenylalanine / analogs & derivatives
-
Phenylalanine / therapeutic use
-
Piperazines
-
Pregnanolone / therapeutic use
-
Pyridones
-
Tropanes / therapeutic use
-
United States
-
United States Food and Drug Administration
-
beta-Cyclodextrins / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Azetidines
-
Benzyl Compounds
-
Carbamates
-
Drug Combinations
-
Heterocyclic Compounds, 3-Ring
-
Nicotinic Acids
-
Oxazines
-
Piperazines
-
Pyridones
-
Tropanes
-
beta-Cyclodextrins
-
brexanolone
-
Lamivudine
-
romosozumab
-
Phenylalanine
-
tazarotene
-
risankizumab
-
solriamfetol
-
halobetasol
-
Clobetasol
-
Pregnanolone
-
dolutegravir
-
siponimod
-
aclidinium bromide
-
Formoterol Fumarate